LENSAR, Inc.

Good morning, and thank you for your participation. At this time, all participants are in the listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to turn the call over to Cameron Radinovic of Burns MacMillan. Mr. Radinovic, please go ahead.

Thank you, Operator. Good morning, and welcome to the Lensar First Quarter 2022 Financial Results Conference Call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended March 31st, 2022. This press release is available on the investor relations section of the company's website at www.lunzar.com. Joining me on the call today is Nick Curtis, Chief Executive Officer of LUNZAR, who will review the company's recent business and operational progress following his comments, Tom Staub, Chief Financial Officer of Lanzar, will provide an overview of the company's financial highlights before turning the call back over to Nick for closing remarks. Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause the company's actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of the company's risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on the website. In addition, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 9, 2022. Lenzar undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live conference call. It is my pleasure to turn the call over to Chief Executive Officer Nick Curtis.

Nick? Thank you, Cameron, and good morning to everyone listening. Thank you for joining us on our first quarter 2022 conference call. We have achieved an impressive start to 2022 by returning to our historical growth trends, as well as delivering on our previously promised critical strategic milestone with the submission and the FDA's subsequent acceptance for substantive review, our 510 filing for Ally. Our first quarter revenue worldwide procedure volumes each increased more than 30% compared to the first quarter 2021. In addition to steady growth in procedure volumes, we have continued to see increases in both system sales and lease placements for our current generation lensar laser system with streamlined and teleaxis refractive capsulorhexis by increasing systems placed on a worldwide basis to approximately 255 systems. This represents a 30-system increase from March 31, 2021. These additional system placements and the associated year-over-year procedure increase represent a strong foundation upon which to launch ALLY and continued validation of the core feature technology advantages of the current LENZAR system in comparison to other femtosecond lasers available in the marketplace. Furthermore, we intend to continue leading innovation by giving refractive cataract surgeons even greater technology performance and procedure efficiencies with ALLY, thereby enabling them to provide highly optimized patient outcomes and provide an overall better patient experience in their cataract surgery procedures. These advancements and commitment to the continuous improvement of our device are at the heart of the reason why US-based Lensar laser systems perform twice as many procedures as the industry average. We've also made tremendous headway in broadening surgeon awareness of Ally, most recently as measured and recognized at the ASCRS a few weeks ago. I would like to highlight some metrics from the ASCRS meeting is it's arguably one of the largest and most relevant U.S. Congresses in our field. Attendance was significantly higher than last year, with nearly 3,000 surgeons attending in person. Furthermore, Lenzar was well represented, with eight podium presentations demonstrating improved patient outcomes and the management of astigmatism with reproducibility and precision that is not seen with manual and other laser technologies. This provides Lensar surgeons the opportunity to broaden use of their lasers to treat more patients because they have the confidence that they can deliver on their patients' expectations and these advanced cataract surgical procedures. We also had the opportunity to invite attendees to a Lensar experts meeting, which consisted of three comprehensive sessions covering a deep dive into user experiences with our current LLS, new clinical data, and review of the first human cases performed with Ally. For the first time, we opened attendance to include a small group of non-Lensar KOLs interested in the adoption of Lensar with Ally. We're thankful to the surgeons that presented their results and shared their experiences as well as to all the attendees. The turnout for these interactive sessions was very encouraging and expanded awareness of Lensar system's capabilities and the ability of our system to play a key role in facilitating better patient care. Over 140 ally demonstrations in total were completed. Over 120 surgeon demonstrations were performed, with 55% of these demos conducted for non-Lensar customers. MarketScope recognized the Lensar booth as one of the busiest at the ASCRS. That's gratifying recognition of our commitment to delivering cutting-edge technology and the enthusiasm surrounding allies. We also achieved a major milestone in the company's history with the submission and subsequent FDA acceptance of our 510K application for regulatory clearance of the Ally in February. Our application is undergoing substantive review by the FDA, and if cleared, we're on track to launch Ally in the second half of 2022. We look forward to continued and productive interactions with the FDA on our filing. Now more than ever, we believe that Ally represents the next great innovation in refractive cataract surgery. It appears this thought is shared by a number of surgeons that were excited to demo Ally for the first time. Ally has the potential to be the first platform in the market to combine a next-generation dual-pulse femtosecond laser with a world-leading Swiss-made faecal emulsification technology in a fully integrated system, allowing surgeons to prep the patient once, perform a sterile flax and cataract procedure. The significantly faster scanning and laser treatment time and not having to move and reprep the patient demonstrated that our patient treatment experience to date indicated a time savings of 10 minutes per case. Ally is a transformative system that integrates current LLS core features, including cataract density imaging, customized fragmentation and energy settings, optimized incisions with proprietary astigmatic guidance technology to adapt to every patient condition, surgeon treatment preference, and the work environment. I look forward to the remainder of 2022 at LensArm, as we have been able to build off the momentum generated in 2021 and the excitement surrounding Ally and the SCRS as confirmation of our beliefs that we're on the verge of revolutionizing the cataract surgery market. We look at this excitement as a strong indicator that our commitment to delivering substantive and meaningful advancements is beginning to pay off. We look forward to updating you on our Ally filing in the coming quarters. And now I'm going to turn the call over to Tom to cover our financial highlights for the quarter. Tom?